ACSL3 and chronic kidney disease: We found that the expression of ferroptosis activator ACSL4 showed a strong negative correlation with kidney function (eGFR) and positive correlation with fibrosis, and the expression of ACSL3 and SLC3A2 showed a positive correlation with eGFR and negative correlation with fibrosis (Fig. 8c), supporting an important role for ferroptosis in patients with CKD and fibrosis.